| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
Treating childhood acute lymphoblastic leukemia without cranial irradiation.
|
N Engl J Med
|
2009
|
7.95
|
|
2
|
Risk-adapted craniospinal radiotherapy followed by high-dose chemotherapy and stem-cell rescue in children with newly diagnosed medulloblastoma (St Jude Medulloblastoma-96): long-term results from a prospective, multicentre trial.
|
Lancet Oncol
|
2006
|
6.92
|
|
3
|
Outcome of treatment in childhood acute lymphoblastic leukaemia with rearrangements of the 11q23 chromosomal region.
|
Lancet
|
2002
|
2.46
|
|
4
|
Multiagent chemotherapy and deferred radiotherapy in infants with malignant brain tumors: a report from the Children's Cancer Group.
|
J Clin Oncol
|
2005
|
2.24
|
|
5
|
Amifostine protects against cisplatin-induced ototoxicity in children with average-risk medulloblastoma.
|
J Clin Oncol
|
2008
|
1.87
|
|
6
|
Phase I trial of imatinib in children with newly diagnosed brainstem and recurrent malignant gliomas: a Pediatric Brain Tumor Consortium report.
|
Neuro Oncol
|
2007
|
1.84
|
|
7
|
Expression of p53 and prognosis in children with malignant gliomas.
|
N Engl J Med
|
2002
|
1.74
|
|
8
|
The influence of central review on outcome associations in childhood malignant gliomas: results from the CCG-945 experience.
|
Neuro Oncol
|
2003
|
1.66
|
|
9
|
Statistical significance threshold criteria for analysis of microarray gene expression data.
|
Stat Appl Genet Mol Biol
|
2004
|
1.62
|
|
10
|
Shortening infusion time for high-dose methotrexate alters antileukemic effects: a randomized prospective clinical trial.
|
J Clin Oncol
|
2011
|
1.60
|
|
11
|
Trial design: The St. Jude Children's Research Hospital Cancer Survivors Tobacco Quit Line study.
|
Contemp Clin Trials
|
2009
|
1.55
|
|
12
|
A molecular biology and phase II trial of lapatinib in children with refractory CNS malignancies: a pediatric brain tumor consortium study.
|
J Neurooncol
|
2013
|
1.51
|
|
13
|
Granulocyte colony-stimulating factor and the risk of secondary myeloid malignancy after etoposide treatment.
|
Blood
|
2003
|
1.51
|
|
14
|
Disenrollment and re-enrollment patterns in a SCHIP.
|
Health Care Financ Rev
|
2002
|
1.50
|
|
15
|
Lack of efficacy of bevacizumab plus irinotecan in children with recurrent malignant glioma and diffuse brainstem glioma: a Pediatric Brain Tumor Consortium study.
|
J Clin Oncol
|
2010
|
1.50
|
|
16
|
Phase I trial of MK-0752 in children with refractory CNS malignancies: a pediatric brain tumor consortium study.
|
J Clin Oncol
|
2011
|
1.39
|
|
17
|
Histopathological grading of pediatric ependymoma: reproducibility and clinical relevance in European trial cohorts.
|
J Negat Results Biomed
|
2011
|
1.39
|
|
18
|
Outcome of children with centrally reviewed low-grade gliomas treated with chemotherapy with or without radiotherapy on Children's Cancer Group high-grade glioma study CCG-945.
|
Cancer
|
2003
|
1.38
|
|
19
|
Phase I trial of single-dose temozolomide and continuous administration of o6-benzylguanine in children with brain tumors: a pediatric brain tumor consortium report.
|
Clin Cancer Res
|
2007
|
1.34
|
|
20
|
Phase I clinical trial of cilengitide in children with refractory brain tumors: Pediatric Brain Tumor Consortium Study PBTC-012.
|
J Clin Oncol
|
2008
|
1.33
|
|
21
|
A pharmacogenetic study of uridine diphosphate-glucuronosyltransferase 2B7 in patients receiving morphine.
|
Clin Pharmacol Ther
|
2003
|
1.31
|
|
22
|
Continual reassessment method vs. traditional empirically based design: modifications motivated by Phase I trials in pediatric oncology by the Pediatric Brain Tumor Consortium.
|
J Biopharm Stat
|
2009
|
1.29
|
|
23
|
Pseudoscore-based estimation from biased observations.
|
Stat Med
|
2007
|
1.20
|
|
24
|
Phase I study of vismodegib in children with recurrent or refractory medulloblastoma: a pediatric brain tumor consortium study.
|
Clin Cancer Res
|
2013
|
1.20
|
|
25
|
Phase I and pharmacokinetic study of the oral farnesyltransferase inhibitor lonafarnib administered twice daily to pediatric patients with advanced central nervous system tumors using a modified continuous reassessment method: a Pediatric Brain Tumor Consortium Study.
|
J Clin Oncol
|
2007
|
1.17
|
|
26
|
Phase I trial of tipifarnib in children with newly diagnosed intrinsic diffuse brainstem glioma.
|
Neuro Oncol
|
2008
|
1.15
|
|
27
|
Evaluation of 18F-FDG PET and MRI associations in pediatric diffuse intrinsic brain stem glioma: a report from the Pediatric Brain Tumor Consortium.
|
J Nucl Med
|
2011
|
1.14
|
|
28
|
A statistical framework to evaluate virtual screening.
|
BMC Bioinformatics
|
2009
|
1.14
|
|
29
|
Impact of proliferation index on outcome in childhood malignant gliomas: results in a multi-institutional cohort.
|
Neurosurgery
|
2002
|
1.12
|
|
30
|
MRI as a central component of clinical trials analysis in brainstem glioma: a report from the Pediatric Brain Tumor Consortium (PBTC).
|
Neuro Oncol
|
2011
|
1.11
|
|
31
|
Phase I trial of lapatinib in children with refractory CNS malignancies: a Pediatric Brain Tumor Consortium study.
|
J Clin Oncol
|
2010
|
1.10
|
|
32
|
A phase I and biology study of gefitinib and radiation in children with newly diagnosed brain stem gliomas or supratentorial malignant gliomas.
|
Eur J Cancer
|
2010
|
1.09
|
|
33
|
De novo purine synthesis inhibition and antileukemic effects of mercaptopurine alone or in combination with methotrexate in vivo.
|
Blood
|
2002
|
1.08
|
|
34
|
A phase II study of gefitinib and irradiation in children with newly diagnosed brainstem gliomas: a report from the Pediatric Brain Tumor Consortium.
|
Neuro Oncol
|
2011
|
1.07
|
|
35
|
Phase II trial of tipifarnib and radiation in children with newly diagnosed diffuse intrinsic pontine gliomas.
|
Neuro Oncol
|
2011
|
1.05
|
|
36
|
Preradiation chemotherapy in primary high-risk brainstem tumors: phase II study CCG-9941 of the Children's Cancer Group.
|
J Clin Oncol
|
2002
|
1.05
|
|
37
|
Phase I trial of lenalidomide in pediatric patients with recurrent, refractory, or progressive primary CNS tumors: Pediatric Brain Tumor Consortium study PBTC-018.
|
J Clin Oncol
|
2010
|
1.00
|
|
38
|
Intratumoral hemorrhage among children with newly diagnosed, diffuse brainstem glioma.
|
Cancer
|
2006
|
0.99
|
|
39
|
Myeloablative chemotherapy with autologous bone marrow rescue in children and adolescents with recurrent malignant astrocytoma: outcome compared with conventional chemotherapy: a report from the Children's Oncology Group.
|
Pediatr Blood Cancer
|
2008
|
0.98
|
|
40
|
Efficacy of bevacizumab plus irinotecan in children with recurrent low-grade gliomas--a Pediatric Brain Tumor Consortium study.
|
Neuro Oncol
|
2013
|
0.98
|
|
41
|
Phase II study of oxaliplatin in children with recurrent or refractory medulloblastoma, supratentorial primitive neuroectodermal tumors, and atypical teratoid rhabdoid tumors: a pediatric brain tumor consortium study.
|
Cancer
|
2006
|
0.97
|
|
42
|
A phase II study of O6-benzylguanine and temozolomide in pediatric patients with recurrent or progressive high-grade gliomas and brainstem gliomas: a Pediatric Brain Tumor Consortium study.
|
J Neurooncol
|
2011
|
0.96
|
|
43
|
Association between chromosome 1p and 19q loss and outcome in pediatric malignant gliomas: results from the CCG-945 cohort.
|
Pediatr Neurosurg
|
2003
|
0.96
|
|
44
|
Phase I study of SU5416, a small molecule inhibitor of the vascular endothelial growth factor receptor (VEGFR) in refractory pediatric central nervous system tumors.
|
Pediatr Blood Cancer
|
2009
|
0.95
|
|
45
|
Phase I trial of VNP40101M (Cloretazine) in children with recurrent brain tumors: a pediatric brain tumor consortium study.
|
Clin Cancer Res
|
2008
|
0.94
|
|
46
|
DTI assessment of the brainstem white matter tracts in pediatric BSG before and after therapy: a report from the Pediatric Brain Tumor Consortium.
|
Childs Nerv Syst
|
2010
|
0.92
|
|
47
|
Lack of efficacy of bevacizumab + irinotecan in cases of pediatric recurrent ependymoma--a Pediatric Brain Tumor Consortium study.
|
Neuro Oncol
|
2012
|
0.92
|
|
48
|
Anaplastic mixed gliomas and anaplastic oligodendroglioma in children: results from the CCG 945 experience.
|
J Neurooncol
|
2007
|
0.91
|
|
49
|
Phase I trial of intrathecal spartaject busulfan in children with neoplastic meningitis: a Pediatric Brain Tumor Consortium Study (PBTC-004).
|
Clin Cancer Res
|
2006
|
0.88
|
|
50
|
M1 Medulloblastoma: high risk at any age.
|
J Neurooncol
|
2008
|
0.87
|
|
51
|
Patterns of failure in supratentorial primitive neuroectodermal tumors treated in Children's Cancer Group Study 921, a phase III combined modality study.
|
Int J Radiat Oncol Biol Phys
|
2004
|
0.86
|
|
52
|
Exploratory evaluation of two-dimensional and three-dimensional methods of FDG PET quantification in pediatric anaplastic astrocytoma: a report from the Pediatric Brain Tumor Consortium (PBTC).
|
Eur J Nucl Med Mol Imaging
|
2008
|
0.85
|
|
53
|
Phase I and pharmacokinetic trial of PTC299 in pediatric patients with refractory or recurrent central nervous system tumors: a PBTC study.
|
J Neurooncol
|
2014
|
0.84
|
|
54
|
Pilot study of systemic and intrathecal mafosfamide followed by conformal radiation for infants with intracranial central nervous system tumors: a pediatric brain tumor consortium study (PBTC-001).
|
J Neurooncol
|
2012
|
0.83
|
|
55
|
Bevacizumab (BVZ)-associated toxicities in children with recurrent central nervous system tumors treated with BVZ and irinotecan (CPT-11): a Pediatric Brain Tumor Consortium Study (PBTC-022).
|
Cancer
|
2013
|
0.83
|
|
56
|
Patterns of treatment failure in infants with primitive neuroectodermal tumors who were treated on CCG-921: a phase III combined modality study.
|
Pediatr Blood Cancer
|
2005
|
0.82
|
|
57
|
An operational perspective of challenging statistical dogma while establishing a modern, secure distributed data management and imaging transport system: the Pediatric Brain Tumor Consortium phase I experience.
|
Clin Transl Sci
|
2009
|
0.82
|
|
58
|
Pharmacokinetics and pharmacodynamics of oral etoposide in children with relapsed or refractory acute lymphoblastic leukemia.
|
J Clin Oncol
|
2003
|
0.82
|
|
59
|
Outcome and prognostic factors for children with supratentorial primitive neuroectodermal tumors treated with carboplatin during radiotherapy: a report from the Children's Oncology Group.
|
Pediatr Blood Cancer
|
2015
|
0.80
|
|
60
|
Combined modality therapy for poorly differentiated gliomas of the posterior fossa in children: a Children's Cancer Group report.
|
J Neurooncol
|
2003
|
0.79
|
|
61
|
Bevacizumab-associated osteonecrosis of the wrist and knee in three pediatric patients with recurrent CNS tumors.
|
J Clin Oncol
|
2012
|
0.78
|
|
62
|
A stochastic model for estimation of mutation rates in multiple-replication proliferation processes.
|
J Math Biol
|
2008
|
0.78
|
|
63
|
Radiation therapy quality in CCG/POG intergroup 9961: implications for craniospinal irradiation and the posterior fossa boost in future medulloblastoma trials.
|
Front Oncol
|
2012
|
0.77
|
|
64
|
Cumulative cisplatin dose is not associated with event-free or overall survival in children with newly diagnosed average-risk medulloblastoma treated with cisplatin based adjuvant chemotherapy: report from the Children's Oncology Group.
|
Pediatr Blood Cancer
|
2013
|
0.77
|
|
65
|
Impact of tumor location and pathological discordance on survival of children with midline high-grade gliomas treated on Children's Cancer Group high-grade glioma study CCG-945.
|
J Neurooncol
|
2014
|
0.75
|
|
66
|
A phase I trial and PK study of cediranib (AZD2171), an orally bioavailable pan-VEGFR inhibitor, in children with recurrent or refractory primary CNS tumors.
|
Childs Nerv Syst
|
2015
|
0.75
|
|
67
|
Benefit from prolonged dose-intensive chemotherapy for infants with malignant brain tumors is restricted to patients with ependymoma: a report of the Pediatric Oncology Group randomized controlled trial 9233/34.
|
Neuro Oncol
|
2013
|
0.75
|
|
68
|
Maximum likelihood estimation of reviewers' acumen in central review setting: categorical data.
|
Theor Biol Med Model
|
2011
|
0.75
|
|
69
|
Phase I trial of capecitabine rapidly disintegrating tablets and concomitant radiation therapy in children with newly diagnosed brainstem gliomas and high-grade gliomas.
|
Neuro Oncol
|
2013
|
0.75
|
|
70
|
Phase I trial of weekly MK-0752 in children with refractory central nervous system malignancies: a pediatric brain tumor consortium study.
|
Childs Nerv Syst
|
2015
|
0.75
|